Researchers from Harvard and Queen Mary University of London found that baxdrostat could permanently treat primary aldosteronism. The trial showed blood pressure normalization persisted for two years after treatment ended.
How Baxdrostat targets the 5% of hypertension cases driven by aldosterone
The drug baxdrostat operates by inhibiting the production of aldosterone, a hormone secreted by the adrenal glands that triggers the kidneys to retain water and salt. according to the report, this specific hormonal overproduction is the primary driver in approximately five percent of all hypertension cases, leading to blood pressure levels that are often resistant to standard treatments.
What makes baxdrostat distinct from traditional antihypertensives is its potential to alter the biological landscape of the disease. The research suggests that suppressing aldosterone may cause the actual cells responsible for the hormone's overproduction to disappear. Rather than merely masking symptoms through daily maintenance, this mechanism targets the root cause, potentially offering a finite treatment window for a permanent recovery.
A 25-point systolic drop across 14 US participants
In a clinical study involving 14 patients in the United States, participants took baxdrostat once daily for a period ranging from six to twelve months. As the report says,the results were significant: average systolic blood pressure fell from 142.4 mmHg to 117.2 mmHg. This reduction of roughly 25 points moved the participants from a "high" classification into the healthy range defined by NHS guidelines.
The most striking finding was the longevity of the effect. two years after the 14 US patients stopped taking the medication, researchers observed a 99 percent decrease in markers associated with excess aldosterone production. This suggests that the drug does not simply lower blood pressure while present in the system,but may fundamentally reset the patient's hormonal balance.
Replacing adrenal surgery for 800,000 Britons
For the estimated 800,000 people in the United Kingdom suffering from primary aldosteronism, the current medical options are often binary: lifelong medication or invasive surgery to remove the adrenal glands. Baxdrostat represents a middle path, offering a "surgical-grade" cure via a tablet, which avoids the inherent risks of operating on endocrine glands.
This development is particularly critical given the scale of the crisis in the UK, where 16 million adults struggle with hypertension.. While primary aldosteronism is a subset of this group, the ability to move patients from chronic management to full remission would significantly reduce the long-term burden on the National Health Service (NHS). Currently, AstraZeneca is seeking approval from UK health regulators to determine the drug's cost-effectiveness for the British market.
The ELIXIR trial and the 2028 window for validation
Despite the promising data, significant gaps in the evidence remain due to the limited scope of the initial study. Professor Morris Brown of Queen Mary University of London has cautioned that a sample size of only 14 people is too small to draw definitive conclusions about the general population . It remains unverified whether this "permanent cure" effect is universal across different demographics or if certain genetic markers make some patients more responsive than others.
To address these uncertainties, the research team is launching the ELIXIR trial. This larger study aims to replicate the initial findings and provide the statistical power necessary for widespread clinical adoption. Full results from the ELIXIR trial are not expected until late 2028, leaving a multi-year gap between these early signals of success and a proven medical standard.
Comments 0